A randomized controlled trial of the effect of febuxostat treatment on and marker endothelial dysfunction and renal progression in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210224005

Enrollment

Registered

2021-02-24

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the effect of oral febuxostat on renal function and markers of endothelial dysfunction in CKD patients. Febuxostat asymptomatic hyperuricemia asymmetric dimethylarginine kidney disease

Interventions

no treatment ,fekixostat 40 mg

No Intervention No treatment,Experimental Drug

control,febuxostat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: CKD stage III-IV serum uric > 7 mg/dL

Exclusion criteria

Exclusion criteria: Treated with PZA, ethambutol, mercaptopurine, AZA, and theophylline Hypersensitivity to febuxostat Established cardiovascular disease Severe hepatic impairment Organ transplant recipients Pregnancy and breast feeding

Design outcomes

Primary

Measure	Time frame
serum asymmetric dimethylarginine (ADMA) 8 weeks level of serum asymmetric dimethylarginine (ADMA)	—

Secondary

Measure	Time frame
eGFR 8 weeks level of eGFR	—

Countries

Thailand

Contacts

Public ContactNanthawut Ninwisut

department of internal medicine, Phramongkutklao Hospital

oshikung99@gmail.com0808455774

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026